RxDoctor Payments Data

Courtney McClendon, APRN

Psychiatric/Mental Health · Yates Center, KSNPI 1962098384

Payments from drug & device makers

$1,474in general payments, 2019–2025

Across 64 payments — averaging $23.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$325
  • Otsuka America Pharmaceutical, Inc.$276
  • Sunovion Pharmaceuticals Inc.$191
  • E.r. Squibb & Sons, L.L.C.$135
  • AbbVie$124
  • Axsome Therapeutics, Inc.$121
  • plus $304 from 6 others

What the payments were for

  • Food & beverage$1,38994%
  • Education$856%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,474 in reported general payments places this provider in the 70th percentile of 404 psychiatric/mental health providers in Kansas.

See all psychiatric/mental health providers in Kansas

Medicare billing

Part B allowed, 2024
$4,533
Medicare patients
15
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate42$154,819
RexultiBrexpiprazole105$147,681
TrintellixVortioxetine Hydrobromide25$11,731
Aripiprazole37$10,378
Paliperidone ErPaliperidone12$8,434
Haloperidol60$2,526
Olanzapine44$2,244
Divalproex Sodium22$2,176
Duloxetine Hcl83$2,130
Guanfacine Hcl ErGuanfacine Hcl12$2,048
Quetiapine Fumarate50$1,744
Divalproex Sodium ErDivalproex Sodium12$1,738
Buspirone Hcl74$1,051
Lurasidone Hcl29$944
Vilazodone Hcl11$938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$17$154,81942 claims
Otsuka America Pharmaceutical, Inc.Rexulti$276$147,681105 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$26$11,73125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 404 psychiatric/mental health providers in Kansas.

Other psychiatric/mental health in Yates Center

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →